CN104257686A - 一种复方硫酸钠硫酸钾硫酸镁的药物组合物及其制备方法和用途 - Google Patents
一种复方硫酸钠硫酸钾硫酸镁的药物组合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN104257686A CN104257686A CN201410480129.7A CN201410480129A CN104257686A CN 104257686 A CN104257686 A CN 104257686A CN 201410480129 A CN201410480129 A CN 201410480129A CN 104257686 A CN104257686 A CN 104257686A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- acid
- sulfate
- water
- powdered flavor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 34
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 title claims abstract description 16
- 229910052939 potassium sulfate Inorganic materials 0.000 title claims abstract description 16
- 235000011151 potassium sulphates Nutrition 0.000 title claims abstract description 16
- 229910052943 magnesium sulfate Inorganic materials 0.000 title claims abstract description 14
- 235000019341 magnesium sulphate Nutrition 0.000 title claims abstract description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 title claims abstract description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 title claims abstract description 10
- 235000011152 sodium sulphate Nutrition 0.000 title claims abstract description 10
- 150000001875 compounds Chemical class 0.000 title abstract description 3
- 239000000796 flavoring agent Substances 0.000 claims abstract description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 36
- 235000019634 flavors Nutrition 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 17
- 239000004376 Sucralose Substances 0.000 claims abstract description 14
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims abstract description 14
- 239000004299 sodium benzoate Substances 0.000 claims abstract description 14
- 235000010234 sodium benzoate Nutrition 0.000 claims abstract description 14
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims abstract description 14
- 235000019408 sucralose Nutrition 0.000 claims abstract description 14
- 230000000968 intestinal effect Effects 0.000 claims description 36
- 238000003756 stirring Methods 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 17
- -1 compound sodium potassium sulfate magnesium sulfate Chemical class 0.000 claims description 14
- 238000005374 membrane filtration Methods 0.000 claims description 14
- 230000002378 acidificating effect Effects 0.000 claims description 12
- 235000013355 food flavoring agent Nutrition 0.000 claims description 12
- 239000008213 purified water Substances 0.000 claims description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 239000012467 final product Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 235000009392 Vitis Nutrition 0.000 claims description 6
- 241000219095 Vitis Species 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 claims description 6
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 claims description 6
- 241000581835 Monodora junodii Species 0.000 claims description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 5
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
- 239000001630 malic acid Substances 0.000 claims description 4
- 235000011090 malic acid Nutrition 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 239000001530 fumaric acid Substances 0.000 claims description 3
- 239000000174 gluconic acid Substances 0.000 claims description 3
- 235000012208 gluconic acid Nutrition 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 235000011007 phosphoric acid Nutrition 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 235000011054 acetic acid Nutrition 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- 239000001369 metatartaric acid Substances 0.000 claims description 2
- 235000011042 metatartaric acid Nutrition 0.000 claims description 2
- 239000001384 succinic acid Substances 0.000 claims description 2
- 235000011044 succinic acid Nutrition 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 4
- 239000011734 sodium Substances 0.000 abstract description 4
- 229910052708 sodium Inorganic materials 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 150000004691 decahydrates Chemical class 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 9
- 238000004140 cleaning Methods 0.000 description 8
- 239000003792 electrolyte Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000003204 osmotic effect Effects 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 238000002052 colonoscopy Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 241000792859 Enema Species 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000013872 defecation Effects 0.000 description 4
- 239000007920 enema Substances 0.000 description 4
- 229940095399 enema Drugs 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 206010014418 Electrolyte imbalance Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000008141 laxative Substances 0.000 description 3
- 230000002475 laxative effect Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 3
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 206010069688 Acute phosphate nephropathy Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- IPQVTOJGNYVQEO-CXZNLNCXSA-N sennoside A Natural products O=C(O)c1cc(O)c2C(=O)c3c(O[C@H]4[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O4)cccc3[C@@H]([C@H]3c4c(c(O)cc(C(=O)O)c4)C(=O)c4c(O[C@H]5[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O5)cccc34)c2c1 IPQVTOJGNYVQEO-CXZNLNCXSA-N 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 101100087414 Arabidopsis thaliana RH20 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 201000009868 osmotic diarrhea Diseases 0.000 description 1
- 208000028719 osmotic diarrheal disease Diseases 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ILRLTAZWFOQHRT-UHFFFAOYSA-N potassium;sulfuric acid Chemical compound [K].OS(O)(=O)=O ILRLTAZWFOQHRT-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- IPQVTOJGNYVQEO-KGFNBKMBSA-N sennoside A Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1[C@@H]2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-KGFNBKMBSA-N 0.000 description 1
- IPQVTOJGNYVQEO-AIFLABODSA-N sennoside B Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1[C@H]2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-AIFLABODSA-N 0.000 description 1
- 229940004991 sennoside b Drugs 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种复方硫酸钠硫酸钾硫酸镁的药物组合物及其制备方法和用途,属医药技术领域。该药物组合物包含以下重量份的组份:十水硫酸钠20-60份,硫酸钾2-5份,七水硫酸镁2-5份,苯甲酸钠0.01-0.1份,三氯蔗糖0.2-0.5份,酸味剂0.2-1.0份,粉末香精0.4-2.5份,水100-260份。本发明还提供该口服液药物组合物的制备方法及其在制备肠道准备用药物中的用途。
Description
技术领域
本发明涉及一种复方口服液药物组合物及其制备方法和用途,具体涉及一种复方硫酸钠硫酸钾硫酸镁的药物组合物及其制备方法和在制备肠道准备用药物中的用途,属医药技术领域。
背景技术
肠道准备是电子肠镜或胶囊内镜检查以及其他经肠道检查或治疗,或各种开腹手术的重要术前准备工作,其效果好坏直接影响到检查或手术的质量;同时,安全有效又舒适的肠道准备方法能减少患者的痛苦,容易被患者接受,能提高患者对检查和治疗的依从性。目前临床使用的中西医肠道准备方法有多种,其研究仍在继续深入。
灌肠法为传统的肠道准备方法,清洁灌肠是灌肠法的一种,是临床使用最广泛的肠道准备方法之一。自制软皂液是常用的一种灌肠液。由于大肠内环境为微碱性pH值7.0~8.4,偏酸性药物会产生刺激性;而软皂pH值在10~11,具有乳化性能,可起到清洁作用。也有用生理盐水或清水术前晚及术晨清洁灌肠。另外,低盐结肠清洁法是那些不能耐受常规准备溶液,容量过剩、准备时间短的结肠镜检病人最有效的代替法。有报道用磷酸氢盐混合溶液20mL(磷酸二氢钠16g,磷酸氢二钠6g,甘油40mL加蒸馏水至100mL后分装)保留灌肠,效果满意。灌肠法虽然可选到清洁肠道效果,但操作繁琐,既增加了护理的工作量,也给病人带来不便和痛苦。仅对于需在短时间内要进行胃肠道检查或手术前的肠道准备,采用此法较为理想。
口服药物导泻法,通过口服渗透性、刺激性、容积性泻药,以达到清洁肠道的目的,是目前常用的方法。目前常用的药物有聚乙二醇电解质散、硫酸镁、番泻叶、甘露醇、磷酸钠盐口服液。
聚乙二醇电解质散的药理作用是服药后几乎不吸收、不分解,以氢键结合水分子,有效增加肠道液体成分,刺激肠蠕动,引起腹泻而达到清洁肠道的目的。该药含无机盐成分与服用的适量水分,保证了肠道与体液之间的水电解质交换平衡,不容易出现电解质紊乱。目前,已被广泛应用于结肠镜检查前的肠道准备。聚乙二醇常见不良反应是腹胀、恶心和呕吐,罕见过敏性反应如荨麻疹。其最主要缺点是费用相对较高。
硫酸镁属渗透性泻药,口服后不被吸收,在肠道内形成一定的渗透压,刺激肠壁使肠蠕动加强而引起排便;同时口服后使小肠释放胆囊收缩素增多,结肠的分节运动增强而加速排便。硫酸镁因其服用方法简便、效果好、价格低廉而广泛应用于临床。口服后要求立即饮水,高渗硫酸镁到达肠腔立即饱和而达到效果,增加肠道清洁度,但大量饮水易引起腹胀、腹痛、恶心、呕吐等不良反应,饮水不够又影响肠道清洁效果。
甘露醇是一种高渗脱水药,经口服后肠道不吸收,通过升高肠腔内的晶体渗透压,阻碍肠腔内水分吸收,促进组织内的水分大量渗入肠腔内,增加肠腔内容物,对肠壁产生机械性刺激,加强加快肠蠕动,促使肠内容物排出体外,达到清洁肠道的作用,由于其口感好、效果好、价格低廉,病人容易接受。甘露醇在肠道细菌的作用下产生甲烷等易燃性气体,在行高频电手术时可能引起气体爆炸的危险,因而在开展镜下治疗的医院一般不采用此法。研究发现,服用甘露醇肠道气泡较多,影响内镜医生的观察,而且结肠镜结果显示肠腔扩大,黏膜水肿、充血、分泌增加,成堆细胞脱落等明显病理性改变。
磷酸钠盐口服液(辉灵)是第三代肠道清洁剂,是一种高渗性清肠剂,主要作用是使结肠远端肠道膨胀而刺激排便反射,同时体内水进入肠道可致渗透性腹泻从而清洁肠腔。因其口感好、病人耐受性好,磷酸钠盐口服液肠道准备方法在西方国家应用较普遍。有报道,口服磷酸钠溶液后发生严重的高磷酸血症,并发少尿型肾衰竭后死亡的病例,可能与胃排空和肾脏排泄功能障碍有关。美国FDA发出警告,称有报告发现做结肠镜检查或其它类似检查前口服磷酸盐药物(OSP)清肠可能与患者发生急性磷酸盐肾病变(一种急性肾病)之间存在关联。
番泻叶是含蒽醌衍生物,其有效成分主要为番泻苷A、番泻苷B,经胃、小肠吸收后在肝中分解,分解产物经血行而兴奋骨盆神经节,收缩大肠而引起腹泻,该药对多种肠道菌有明显的抑制作用,大剂量服用番泻叶容易引起腹痛、呕吐等不良反应,病人耐受性差,尤其是老年病人。病人排便次数多,水电解质大量丢失,造成脱水甚至水电解质紊乱。
因此,目前临床上还需要一种安全有效、使用方便、低容量、不产生临床上显著体液或电解质变化的理想的肠道准备用药物。
发明内容
本发明的目的在于提供一种复方硫酸钠硫酸钾硫酸镁的药物组合物及其制备方法,用于一种肠道准备药物的制备。
本发明的目的是通过如下技术方案实现的:
一种复方硫酸钠硫酸钾硫酸镁的药物组合物,包含以下组份:十水硫酸钠,硫酸钾,七水硫酸镁,苯甲酸钠,三氯蔗糖,酸味剂,粉末香精,水。
组合物中所述各组份的重量份为:十水硫酸钠20-60份,硫酸钾2-5份,七水硫酸镁2-5份,苯甲酸钠0.01-0.1份,三氯蔗糖0.2-0.5份,酸味剂0.2-1.0份,粉末香精0.4-2.5份,水80-260份。
进一步,所述各组份的重量份为:十水硫酸钠35-45份,硫酸钾2-4份,七水硫酸镁2-4份,苯甲酸钠0.04-0.07份,三氯蔗糖0.2-0.4份,酸味剂0.3-0.7份,粉末香精0.5-1.7份,水100-180份。
组合物中,所述酸味剂选自磷酸、柠檬酸、乳酸、酒石酸、偏酒石酸、苹果酸、延胡索酸、抗坏血酸、葡萄糖酸、乙酸、琥珀酸中的一种或多种的混合。
组合物中,所述粉末香精选自青苹果粉末香精,柠檬粉末香精,葡萄粉末香精中的一种或多种的混合。
进一步,组合物中所述水为纯化水。
通过如下步骤制备本组合物:
(1)取配制量70%的水,加热至60℃以上;
(2)按处方量加入硫酸钠、硫酸钾、硫酸镁、苯甲酸钠、三氯蔗糖,搅拌溶解;
(3)加热煮沸30分钟;
(4)待药液冷却至40℃以下,按处方量加入酸味剂和粉末香精,搅拌溶解;
(5)0.45μm滤膜过滤;
(6)补加纯化水至全量,搅拌均匀;
(7)0.22μm滤膜过滤;
(8)灌封,即得。
进一步,上述步骤中所述水为纯化水。
本发明提供的药物组合物用于肠道准备用药物的制备。
本发明药物组合物具有以下优点:
(1)本发明提供了一种新的肠道准备用口服液药物组合物,满足了临床需要。
(2)本发明药物组合物中三种硫酸盐属于容积性泻药(盐类泻药),在肠道难以吸收,大量口服形成高渗压而阻止肠内水分的吸收,扩张肠道,刺激肠壁,促进肠道蠕动。
(3)本发明药物组合物用于肠道准备,不产生临床上显著体液或电解质的变化。口服磷酸盐药物清肠,磷酸盐的吸收,可能会促进肾脏磷酸钙晶体的沉积,产生急性磷酸盐肾病变(一种急性肾病)。通常硫酸盐比磷酸盐吸收更差,难以吸收,硫酸盐相比磷酸盐产生的电解质和液体的变化更少,是理想的清肠成份。
(4)本发明药物组合物可以提供钠、钾离子,肠道吸收部分钠、钾离子,纠正了电解质紊乱,使不良反应的发生率明显降低。
(5)低容量。相比聚乙二醇电解质,患者服用量少,顺应性高。
(6)原料硫酸钾、硫酸钠、硫酸镁都是无机盐,成本低。
(7)本发明特定比例酸味剂和粉末香精的加入,屏蔽了药物强烈的苦、咸味,改善了口感,使患者易于接受,提高了患者服药的顺应性。
本发明的有益效果:
本发明药物组合物中硫酸盐能提供吸收性差的硫酸根阴离子,未被吸收的硫酸根阴离子和相应阳离子的渗透作用,导致水分滞留在肠道内。当大量水进入体内后,由于未被吸收的离子的渗透作用,使水分滞留在肠道,从而产生水样腹泻。
用本发明药物组合物对比格犬进行了28天的口服毒性研究,最大日剂量为5g/kg/day,均引起了水样腹泻,结肠镜检查显示结肠清洁成功有效率高达98%,极少粪便/液体附着,等级达“极好”级。高剂量组未见有肾脏微观变化。用聚乙二醇电解质散作平行实验,结肠镜检查显示结肠清洁成功有效率达90%,少量粪便/液体附着,不影响检查,等级为“好”级。
本发明药物组合物中硫酸盐的主要排泄途径是粪便排泄。6名健康受试者,第一次半剂量给药后,硫酸盐血清浓度达峰时间(Tmax)为17小时,第二次半剂量给药后,达峰时间为5小时,随后以半衰期8.5小时消除。
本发明药物组合物含特定比例的不同种类的酸味剂和粉末香精,矫正了硫酸盐的苦咸味,增强了无机盐口服液的适口性。
具体实施方式
以下的具体实施方式是对本发明的进一步说明,不应被认为是本发明保护范围的限制。
实施例1:复方硫酸钠硫酸钾硫酸镁的药物组合物的制备
处方:
工艺:
(1)取配制量70%的水,加热至60℃以上;
(2)按处方量加入硫酸钠、硫酸钾、硫酸镁、苯甲酸钠、三氯蔗糖,搅拌溶解;
(3)加热煮沸30分钟;
(4)待药液冷却至40℃以下,按处方量加入苹果酸、柠檬酸、青苹果粉末香精、柠檬粉末香精、葡萄粉末香精,搅拌溶解;
(5)0.45μm滤膜过滤;
(6)补加纯化水至全量,搅拌均匀;
(7)0.22μm滤膜过滤;
(8)灌封,即得。
实施例2:复方硫酸钠硫酸钾硫酸镁的药物组合物的制备
处方:
工艺:
(1)取配制量70%的水,加热至60℃以上;
(2)按处方量加入硫酸钠、硫酸钾、硫酸镁、苯甲酸钠、三氯蔗糖,搅拌溶解;
(3)加热煮沸30分钟;
(4)待药液冷却至40℃以下,按处方量加入乳酸、延胡索酸、柠檬粉末香精、葡萄粉末香精,搅拌溶解;
(5)0.45μm滤膜过滤;
(6)补加纯化水至全量,搅拌均匀;
(7)0.22μm滤膜过滤;
(8)灌封,即得。
实施例3:复方硫酸钠硫酸钾硫酸镁的药物组合物的制备
处方:
工艺:
(1)取配制量70%的水,加热至60℃以上;
(2)按处方量加入硫酸钠、硫酸钾、硫酸镁、苯甲酸钠、三氯蔗糖,搅拌溶解;
(3)加热煮沸30分钟;
(4)待药液冷却至40℃以下,按处方量加入酒石酸、葡萄糖酸、青苹果粉末香精、柠檬粉末香精,搅拌溶解;
(5)0.45μm滤膜过滤;
(6)补加纯化水至全量,搅拌均匀;
(7)0.22μm滤膜过滤;
(8)灌封,即得。
实施例4:复方硫酸钠硫酸钾硫酸镁的药物组合物的制备
处方:
工艺:
(1)取配制量70%的水,加热至60℃以上;
(2)按处方量加入硫酸钠、硫酸钾、硫酸镁、苯甲酸钠、三氯蔗糖,搅拌溶解;
(3)加热煮沸30分钟;
(4)待药液冷却至40℃以下,按处方量加入琥珀酸、葡萄粉末香精,搅拌溶解;
(5)0.45μm滤膜过滤;
(6)补加纯化水至全量,搅拌均匀;
(7)0.22μm滤膜过滤;
(8)灌封,即得。
实施例5:复方硫酸钠硫酸钾硫酸镁的药物组合物的制备
处方:
工艺:
(1)取配制量70%的水,加热至60℃以上;
(2)按处方量加入硫酸钠、硫酸钾、硫酸镁、苯甲酸钠、三氯蔗糖,搅拌溶解;
(3)加热煮沸30分钟;
(4)待药液冷却至40℃以下,按处方量加入苹果酸、磷酸、青苹果粉末香精、柠檬粉末香精、葡萄粉末香精,搅拌溶解;
(5)0.45μm滤膜过滤;
(6)补加纯化水至全量,搅拌均匀;
(7)0.22μm滤膜过滤;
(8)灌封,即得。
实施例6:加速试验
分别取上述实施例1、3、5制备的样品,用口服液体药用聚酯瓶包装,于温度为40±2℃、相对湿度为20±5%的条件下放置6个月,分别于第0、1、3、6个月末取样,考察性状、含量等指标,结果分别见下表1、2、3。
表1加速试验检测结果(实施例1样品)
表2加速试验检测结果(实施例3样品)
表3加速试验检测结果(实施例5样品)
加速试验考察结果表明:用口服液体药用聚酯瓶包装,在40±2℃/RH20±5%条件下放置1、3、6个月后,样品各项检查指标与0月结果相比无明显变化,结果稳定。
Claims (9)
1.一种复方硫酸钠硫酸钾硫酸镁的药物组合物,其特征在于,包含以下组份:十水硫酸钠,硫酸钾,七水硫酸镁,苯甲酸钠,三氯蔗糖,酸味剂,粉末香精,水。
2.根据权利要求1 所述的药物组合物,其特征在于,所述各组份的重量份为:十水硫酸钠20-60份,硫酸钾2-5份,七水硫酸镁2-5份,苯甲酸钠0.01-0.1份,三氯蔗糖0.2-0.5份,酸味剂0.2-1.0份,粉末香精0.4-2.5份,水80-260份。
3.根据权利要求2所述的药物组合物,其特征在于,所述各组份的重量份为:十水硫酸钠35-45份,硫酸钾2-4份,七水硫酸镁2-4份,苯甲酸钠0.04-0.07份,三氯蔗糖0.2-0.4份,酸味剂0.3-0.7份,粉末香精0.5-1.7份,水100-180份。
4.根据权利要求1-3 所述的药物组合物,其特征在于,所述酸味剂选自磷酸、柠檬酸、乳酸、酒石酸、偏酒石酸、苹果酸、延胡索酸、抗坏血酸、葡萄糖酸、乙酸、琥珀酸中的一种或多种的混合。
5.根据权利要求1-3 所述的药物组合物,其特征在于,所述粉末香精选自青苹果粉末香精,柠檬粉末香精,葡萄粉末香精中的一种或多种的混合。
6.根据权利要求1-3 所述的药物组合物,其特征在于,所述水为纯化水。
7.制备权利要求1-3所述药物组合物的方法,其特征在于,包括如下步骤:
(1)取配制量70%的水,加热至60℃以上;
(2)按处方量加入硫酸钠、硫酸钾、硫酸镁、苯甲酸钠、三氯蔗糖,搅拌溶解;
(3)加热煮沸30分钟;
(4)待药液冷却至40℃以下,按处方量加入酸味剂和粉末香精,搅拌溶解;
(5)0.45 滤膜过滤;
(6)补加纯化水至全量,搅拌均匀;
(7)0.22滤膜过滤;
(8)灌封,即得。
8.根据权利要求7所述的制备方法,其特征在于,所述水为纯化水。
9.权利要求1-8所述药物组合物在制备肠道准备用药物中的用途。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410480129.7A CN104257686A (zh) | 2014-09-19 | 2014-09-19 | 一种复方硫酸钠硫酸钾硫酸镁的药物组合物及其制备方法和用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410480129.7A CN104257686A (zh) | 2014-09-19 | 2014-09-19 | 一种复方硫酸钠硫酸钾硫酸镁的药物组合物及其制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104257686A true CN104257686A (zh) | 2015-01-07 |
Family
ID=52149343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410480129.7A Pending CN104257686A (zh) | 2014-09-19 | 2014-09-19 | 一种复方硫酸钠硫酸钾硫酸镁的药物组合物及其制备方法和用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104257686A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110339158A (zh) * | 2019-08-21 | 2019-10-18 | 扬子江药业集团上海海尼药业有限公司 | 一种硫酸钠钾镁口服溶液及其制备方法 |
| CN110652527A (zh) * | 2019-10-28 | 2020-01-07 | 高庆芬 | 硫酸镁口服液 |
| CN116509809A (zh) * | 2023-04-19 | 2023-08-01 | 山东齐都药业有限公司 | 复方硫酸钠片剂及其制备方法与应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090258090A1 (en) * | 2008-04-11 | 2009-10-15 | Braintree Laboratories, Inc. | Colon cleansing solution |
-
2014
- 2014-09-19 CN CN201410480129.7A patent/CN104257686A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090258090A1 (en) * | 2008-04-11 | 2009-10-15 | Braintree Laboratories, Inc. | Colon cleansing solution |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110339158A (zh) * | 2019-08-21 | 2019-10-18 | 扬子江药业集团上海海尼药业有限公司 | 一种硫酸钠钾镁口服溶液及其制备方法 |
| CN110339158B (zh) * | 2019-08-21 | 2020-11-13 | 扬子江药业集团上海海尼药业有限公司 | 一种硫酸钠钾镁口服溶液及其制备方法 |
| CN110652527A (zh) * | 2019-10-28 | 2020-01-07 | 高庆芬 | 硫酸镁口服液 |
| CN116509809A (zh) * | 2023-04-19 | 2023-08-01 | 山东齐都药业有限公司 | 复方硫酸钠片剂及其制备方法与应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109908142B (zh) | 肠清洁组合物 | |
| US6946149B2 (en) | Salt solution for colon cleansing | |
| US9149493B2 (en) | Compositions for bowel cleansing and use thereof | |
| JP6655391B2 (ja) | Pegとアスコルビン酸塩とを含む組成物 | |
| CN105963701A (zh) | 用于肠道清洁的方法、组合物以及包装 | |
| JP6678635B2 (ja) | 大腸内視鏡検査前処置 | |
| US20090258090A1 (en) | Colon cleansing solution | |
| EP2676667A1 (en) | Polyethylene glycol colonic purgative composition | |
| EP2322190B1 (en) | Compositions for bowel cleansing and use thereof | |
| CN104257686A (zh) | 一种复方硫酸钠硫酸钾硫酸镁的药物组合物及其制备方法和用途 | |
| WO2022055286A1 (ko) | 장 정결용 조성물 | |
| CN116509809A (zh) | 复方硫酸钠片剂及其制备方法与应用 | |
| WO2022055287A1 (ko) | 장 정결용 보조 음료 | |
| WO2015056897A1 (ko) | 장 세정용 조성물 | |
| AU2018327614B2 (en) | Composition for calcium supplementation | |
| US12433914B2 (en) | Methods of administering safe colon cleansing compositions | |
| DE102006001199A1 (de) | Fixe Kombination von Substanzen unter Beigabe von Entschäumern zum Einsatz als Darmspüllösung und/oder Laxans | |
| ES2896689T3 (es) | Composición para el tratamiento del estreñimiento | |
| US20200352855A1 (en) | Colon Cleansing Composition and Methods of Using Same | |
| CN107158031A (zh) | 一种磷酸钠盐口服溶液 | |
| CN117179209A (zh) | 一种护胃功效苏打水及其制备方法 | |
| Cittadini | A simple, innocuous and effective method for cleansing the large bowel without enemas | |
| Abrahams et al. | Urinary Stone Inhibitors: Citrate and Magnesium | |
| CN110339158A (zh) | 一种硫酸钠钾镁口服溶液及其制备方法 | |
| HK40022725A (zh) | 用於钙补充的组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150107 |
|
| RJ01 | Rejection of invention patent application after publication |